José Manuel Molina-Guijarro

José Manuel Molina-Guijarro

Auto-generated profile, based on publicly available information

José Manuel Molina-Guijarro

Departamento de Biomedicina y Biotecnología, Universidad de Alcalá, Alcalá de Henares, Spain

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2013 in Nature Communications
Verified
Journal Article
Closed access
PDF file
MPMarta Pelay-Gimeno
Marta Pelay-Gimeno
YGYésica García-Ramos
Yésica García-Ramos
MMMaria Jesús Martin
Maria Jesús Martin
JSJan Spengler
Jan Spengler
JMJosé Manuel Molina-Guijarro
José Manuel Molina-Guijarro
Fernando AlbericioFernando Albericio
Fernando Albericio

1 February 2020 in Biochemical Pharmacology
Verified
Journal Article
Closed access
ALAlejandro Losada
Alejandro Losada
JBJuan José Berlanga
Juan José Berlanga
JMJosé Manuel Molina-Guijarro
José Manuel Molina-Guijarro
AJAntonio Jiménez-Ruiz
Antonio Jiménez-Ruiz
FGFederico Gago
Federico Gago
MFMartinez-Leal Juan Fernando
Martinez-Leal Juan Fernando

27 April 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JMJosé M. Molina-Guijarro
José M. Molina-Guijarro
Álvaro MacíasÁlvaro Macías
Álvaro Macías
CGCarolina García
Carolina García
EMEva Muñoz
Eva Muñoz
LGLuis F. García-Fernández
Luis F. García-Fernández
Carlos María GalmariniCarlos María Galmarini
Carlos María Galmarini
Irvalec is a marine-derived antitumor agent currently undergoing phase II clinical trials. In vitro, Irvalec induces a rapid loss of membrane integrity in tumor cells, accompanied of a significant Ca2+ influx, perturbations of membrane conductivity, severe swelling and the formation of giant membranous vesicles. All these effects are not observed in Irvalec-resistant cells, or are significantly delayed by pretreating the cells with Zn2+. Using fluorescent derivatives of Irvalec it was demonstrated that the compound rapidly interacts with the plasma membrane of tumor cells promoting lipid bilayer restructuration. Also, FRET experiments demonstrated that Irvalec molecules localize in the cell membrane close enough to each other as to suggest that the compound could self-organize, forming supramolecular structures that likely trigger cell death by necrosis through the disruption of membrane integrity.

20 October 2020 in Cancers
Verified
Journal Article
Open access
PDF file
APAdrián Povo-Retana
Adrián Povo-Retana
MMMarina Mojena
Marina Mojena
ASAdrian B. Stremtan
Adrian B. Stremtan
BGBárbara Victoria Fernández García
Bárbara Victoria Fernández García
AGAna Gómez-Sáez
Ana Gómez-Sáez
Lisardo BoscáLisardo Boscá
Lisardo Boscá
Background: Tumor-associated macrophages (TAMs) play a crucial role in suppressing the immunosurveillance function of the immune system that prevents tumor growth. Indeed, macrophages can also be targeted by different chemotherapeutic agents improving the action over immune checkpoints to fight cancer. Here we describe the effect of trabectedin and lurbinectedin on human macrophage cell viability and function. Methods: Blood monocytes from healthy donors were differentiated into macrophages and exposed to different stimuli promoting functional polarization and differentiation into tumor-associated macrophages. Cells were challenged with the chemotherapeutic drugs and the effects on cell viability and function were analyzed. Results: Human macrophages exhibit at least two different profiles in response to these drugs. One-fourth of the blood donors assayed (164 individuals) were extremely sensitive to trabectedin and lurbinectedin, which promoted apoptotic cell death. Macrophages from other individuals retained viability but responded to the drugs increasing reactive oxygen production and showing a rapid intracellular calcium rise and a loss of mitochondrial oxygen consumption. Cell-membrane exposure of programmed-death ligand 1 (PD-L1) significantly decreased after treatment with therapeutic doses of these drugs, including changes in the gene expression profile of hypoxia-inducible factor 1 alpha (HIF-1α)-dependent genes, among other. Conclusions: The results provide evidence of additional onco-therapeutic actions for these drugs.

1 April 2018 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
PAPablo Avilés
Pablo Avilés
JDJuan Manuel Domínguez
Juan Manuel Domínguez
MGMaría José Guillén
María José Guillén
MMMaría José Muñoz-Alonso
María José Muñoz-Alonso
CMCristina Mateo
Cristina Mateo
CCCarmen Cuevas
Carmen Cuevas
In the search for novel payloads to design new antibody–drug conjugates (ADC), marine compounds represent an interesting opportunity given their unique chemical features. PM050489 is a marine compound that binds β-tubulin at a new site and disrupts the microtubule network, hence leading to mitotic aberrations and cell death. PM050489 has been conjugated to trastuzumab via Cys residues through a noncleavable linker, and the resulting ADC, named MI130004, has been studied. Analysis of MI130004 delivered data consistent with the presence of two molecules of PM050489 per antibody molecule, likely bound to both sides of the intermolecular disulfide bond connecting the antibody light and heavy chains. The antitumor activity of MI130004 was analyzed in vitro and in vivo in different cell lines of diverse tumor origin (breast, ovary, and gastric cancer) expressing different levels of HER2. MI130004 showed very high in vitro potency and good selectivity for tumor cells that overexpressed HER2. At the cellular level, MI130004 impaired tubulin polymerization, causing disorganization and disintegration of the microtubule network, which ultimately led to mitotic failure, mirroring the effect of its payload. Treatment with MI130004 in mice carrying histologically diverse tumors expressing HER2 induced a long-lasting antitumor effect with statistically significant inhibition of tumor growth coupled with increases in median survival time compared with vehicle or trastuzumab. These results strongly suggest that MI130004 is endowed with remarkable anticancer activity and confirm the extraordinary potential of marine compounds for the design of new ADCs. Mol Cancer Ther; 17(4); 786–94. ©2018 AACR.

4 March 2025 in Microbial Biotechnology
Verified
Journal Article
Open access
JGJessica Gil‐Serna
Jessica Gil‐Serna
PAPatricia Antunes
Patricia Antunes
SCSusana Campoy
Susana Campoy
ÁCÁngeles Cid
Ángeles Cid
ACAntonio Cobo‐Molinos
Antonio Cobo‐Molinos
APall members of MicroMundo Teams in Spain and Portugal
all members of MicroMundo Teams in Spain and Portugal
Antimicrobial resistance (AMR) poses a global threat to human, animal and environmental health. Among the multidisciplinary tasks aimed at collectively tackling the AMR crisis, surveillance, research and education stand as major priorities. Based on a crowdsourcing research strategy, the MicroMundo project, a partner of the Tiny Earth initiative in Spain and Portugal, has been developed and consolidated with success in the academic environment. The objectives are focused on promoting research and, especially, on bringing knowledge of One Health and microbiology concepts, as well as AMR awareness to the community. Following a service‐learning approach, MicroMundo integrates university and secondary/high school students in a citizen science‐based research project to collectively isolate microorganisms with the potential to produce new antibiotics from soil environments. Over the last 7 years, 32 MicroMundo hubs operating across 31 different Portuguese and Spanish universities have recruited thousands of teenagers in this quest. Here we review the outcome of this unprecedented effort from a scientific and an educational perspective.